A Capsida scientist at work in the company’s laboratory in Thousand Oaks. (courtesy photo) Thousand Oaks-based Capsida ...
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with AbbVie Inc. (NYSE: ABBV) to include the discovery of T ...
NORTH CHICAGO, Ill. and ROCKVILLE, Md., Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program. ABBV-RGX-314 ...
AbbVie will take an impairment charge of approximately $3.5 billion related to the back-to-back failures of its pricey drug candidate emraclidine in two mid-stage schizophrenia trials, the pharma ...
Movers & Shakers: Ardagh, Disney, Alvarez & Marsal, Lauder Teacher, AbbVie, 150Bond, Dublin Gazette Business Post head of news Peter O’Dwyer reveals who’s on the move in the entertainment, legal, ...
AbbVie Inc. will record a $3.5 billion charge after a schizophrenia drug it gained in the purchase of Cerevel Therapeutics Inc. failed in clinical trials. The experimental drug, emraclidine, failed to ...
AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on January 6. Analyst David Risinger from Leerink Partners maintained a Buy rating on the ...
AbbVie will clearly fight to keep its top-selling Humira (adalimumab) anti-inflammatory drug on the market for as long as possible – but it also has one eye on a possible successor that is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback